WO1979000638A1 - Methode de production de surfaces permettant d'eviter la formation de thrombus - Google Patents
Methode de production de surfaces permettant d'eviter la formation de thrombus Download PDFInfo
- Publication number
- WO1979000638A1 WO1979000638A1 PCT/SE1979/000035 SE7900035W WO7900638A1 WO 1979000638 A1 WO1979000638 A1 WO 1979000638A1 SE 7900035 W SE7900035 W SE 7900035W WO 7900638 A1 WO7900638 A1 WO 7900638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparin
- hirudin
- salt
- metal
- palladium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000007536 Thrombosis Diseases 0.000 title abstract description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920000669 heparin Polymers 0.000 claims abstract description 21
- 229960002897 heparin Drugs 0.000 claims abstract description 21
- 229910052751 metal Inorganic materials 0.000 claims abstract description 19
- 239000002184 metal Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 102000007625 Hirudins Human genes 0.000 claims abstract description 10
- 108010007267 Hirudins Proteins 0.000 claims abstract description 10
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 10
- 229940006607 hirudin Drugs 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002506 anticoagulant protein Substances 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 150000002940 palladium Chemical class 0.000 claims abstract description 4
- 238000009736 wetting Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 230000001427 coherent effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 abstract description 2
- 238000009877 rendering Methods 0.000 abstract description 2
- 150000003283 rhodium Chemical class 0.000 abstract description 2
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical group NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- LCTORNIWLGOBPB-DVKNGEFBSA-N (2s,3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound N[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-DVKNGEFBSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- -1 acryl Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0017—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a surface active agent
Definitions
- the present invention relates to a novel method of effect ⁇ ively treating surfaces with heparin, hirudin and other anticoagulant proteins for the purpose of rendering said surfaces resistant to thrombosis.
- the method comprises the treatment of said surface with a palladium salt or a rhodium salt prior to heparising said surface.
- Heparin which is a mucopolysaccharide from D-glucoseamine and glucuronic acid with a molecular weight of about 17000, has the ability of preventing the aforementioned formation of a thrombus. It is essential that a heparinized surface is stable and that the heparin is firmly bound to the surface of the object.
- -stage method of heparinizing a surface which method, in addition to washing stages, comprises treating the surface with hexadecyl amine hydrochloride heparin, an aminesoluti t glutaraldehyde and cooking salt.
- the product is considerab better than one whose surfaces have not been treated.
- the layers produced when applying this method tend to be uneve and are also liable to be washed-off by the blood flowing thereagainst, consequently, there is a need of improving the method.
- Heparin shares this property with hirudin and other anticoagulant proteins.
- Hirudin is a protein having a molecular weight of 16000 - 1000.
- the surface to be treated may be of practically any materi whatsoever, although preferably the surface is of metal, such as a stainless steel, a plastics material, such as polyvinyl chloride, polyolefins, acryl resins and co-poly ⁇ mers thereof, silicon plastics, rubber, particularly butyl rubber, and fluorocarbon plastics.
- metal such as a stainless steel
- plastics material such as polyvinyl chloride, polyolefins, acryl resins and co-poly ⁇ mers thereof, silicon plastics, rubber, particularly butyl rubber, and fluorocarbon plastics.
- the treatment metal may be one of a number of different metals. Those metals tested in particular included palladium, rhodium, nickel, cobalt and copper. Among these metals palladium and rhodium take a particular position, owing to the fact that peptide hydrogen ionisation takes place at an optimal pH range of 3-4. The pH range in the case of nickel is 4-6, in the case of cobalt 6-8 and in the case of copper 8-10. With regard to these properties see E.W. Wilson and R.B. Martin, Inorg. Chem 9, page 528 (1970).
- the well-cleaned, and optionally etched surface is treated with a solution of a metal salt of the metal soluble in the solvent used, with a preferably pharmaceutically acceptable acid.
- a suitable solvent there can be mentioned primarily water, and water in mix ⁇ tures with a polar solvent m-iscible therewith.
- Polar organic solvents can also be used. Among those polar solvents which can be used are alkanols, such as methanol and ethanol.
- Suitable salts are primarily chlorides, sul ⁇ phates, nitrates, acetates, citrates, although it lies within the expertise of one skilled in this art to select other suitable soluble salts of the metal used.
- Rhodium can be used in the same manner.
- the treatment with the metal salt takes only some seccnds up to some minutes, depending upon the temperature of the solution and its pH, and takes place at an ion strength o 0.3-3 mmol metal salt per litre, which in the case of the mentioned palladium salts corresponds to 0.1-0.5 grams of salt per litre.
- the temperature may be room temperature, although a temperature of 50-80 c C is preferred.
- the surface is treated with a heparin solution containing 1000-10000 IE heparin per litre.
- the solution contains mainly water and other suitable substances such as sodium chloride and glucose.
- the treatment time also varies here, although normally requires a treatment time 15-45 minutes. Glucose can be added to stabilise the solu tion.
- the treatment method proposed in accordance with the in ⁇ vention results in the formation of a heparin layer which, has been judged, on the tests carried out, to be some ten times better than a heparin layer produced in accordance with the present standpoint of technics. It is assumed th palladium binds to the amine group in the glucose amine part of the heparin molecule, possibly in combination with van den Waals bonds to oxygen atoms in the heparin chain and in the sulphone group which is bound to the amine gro in the glucose amine part of the molecule.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Une methode de traitement de surfaces d'instruments a usage medical destines a etre en contact avec le sang ou le plasma sanguin dans le but de conferer aux surfaces un effet s'opposant a la formation de thrombus. Les surfaces sont traitees avec une solution de mouillage d'un sel d'un metal capable de provoquer une ionisation hydrogene peptide et de former des composes complexes avec l'heparine, l'hirudine et des proteines coagulantes autres que l'hirudine, tel qu'un sel de rhodium ou un sel de palladium, avant d'y appliquer une couche d'heparine, d'hirudine ou des proteines anticoagulantes autres que l'hirudine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7801853 | 1978-02-17 | ||
| SE7801853 | 1978-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1979000638A1 true WO1979000638A1 (fr) | 1979-09-06 |
Family
ID=20334023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1979/000035 WO1979000638A1 (fr) | 1978-02-17 | 1979-02-16 | Methode de production de surfaces permettant d'eviter la formation de thrombus |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0015909A1 (fr) |
| JP (1) | JPS55500091A (fr) |
| DK (1) | DK427079A (fr) |
| WO (1) | WO1979000638A1 (fr) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0357242A1 (fr) * | 1988-08-03 | 1990-03-07 | New England Deaconess Hospital Corporation | Substance bio-compatible et thromboréristante revêtue d'hirudine, des ses analoges ou de ces fragments, ainsi que sa méthode de production |
| WO1991002750A1 (fr) * | 1989-08-18 | 1991-03-07 | Biogen, Inc. | Nouveaux inhibiteurs de thrombine |
| EP0367489A3 (fr) * | 1988-11-01 | 1991-07-31 | Baxter International Inc. | Matériaux antithrombosiques et leur méthode de préparation |
| EP0442843A1 (fr) * | 1990-02-14 | 1991-08-21 | Pentapharm A.G. | Inhibiteur pour le prétraitement anticoagulant des échantillons sanguins |
| WO1992005749A1 (fr) * | 1990-10-04 | 1992-04-16 | New England Deaconess Hospital Corporation | Conjugues solubles d'un inhibiteur de la thrombogenese |
| US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
| US5135516A (en) * | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
| WO1993010827A1 (fr) * | 1991-11-29 | 1993-06-10 | William Cook Europe A/S | Procede d'application d'un revetement hydrophile sur des surfaces en metal |
| US5281662A (en) * | 1988-08-03 | 1994-01-25 | New England Deaconess Hospital Corporation | Anthraquinone dye treated materials |
| US7371257B2 (en) | 1989-12-15 | 2008-05-13 | Boston Scientific Scimed, Inc. | Stent lining |
| CN112043877A (zh) * | 2020-08-06 | 2020-12-08 | 苏州大学 | 一种蚕丝抗凝血管支架覆膜及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819079A1 (de) * | 1988-06-04 | 1989-12-07 | Hoechst Ag | Hirudin-derivate mit verzoegerter wirkung |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2702253A (en) * | 1950-11-01 | 1955-02-15 | Gasaccumulator Svenska Ab | Surface metallizing method |
| US3549409A (en) * | 1969-04-28 | 1970-12-22 | Cordis Corp | Production of nonthrombogenic plastics |
-
1979
- 1979-02-16 JP JP50042479A patent/JPS55500091A/ja active Pending
- 1979-02-16 WO PCT/SE1979/000035 patent/WO1979000638A1/fr unknown
- 1979-09-11 EP EP19790900219 patent/EP0015909A1/fr not_active Withdrawn
- 1979-10-10 DK DK427079A patent/DK427079A/da not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2702253A (en) * | 1950-11-01 | 1955-02-15 | Gasaccumulator Svenska Ab | Surface metallizing method |
| US3549409A (en) * | 1969-04-28 | 1970-12-22 | Cordis Corp | Production of nonthrombogenic plastics |
Non-Patent Citations (2)
| Title |
|---|
| Chalmers. Tidskrift utgiven av Chalmers Tekniska Hogskola, No. 2 1971, issued 1971 (Goteborg, Sweden) "Heparin", see pages 4 to 6. * |
| Journal of Biomedical Materials Research, Volume 6, Pt 1, issued 1972 (New York), M F DYCK, "Inorganic Heparin Complexes for the Preparation of Nonthrombogenic Surfaces", see pages 115 to 141. * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281662A (en) * | 1988-08-03 | 1994-01-25 | New England Deaconess Hospital Corporation | Anthraquinone dye treated materials |
| EP0357242A1 (fr) * | 1988-08-03 | 1990-03-07 | New England Deaconess Hospital Corporation | Substance bio-compatible et thromboréristante revêtue d'hirudine, des ses analoges ou de ces fragments, ainsi que sa méthode de production |
| US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
| US5167960A (en) * | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
| EP0367489A3 (fr) * | 1988-11-01 | 1991-07-31 | Baxter International Inc. | Matériaux antithrombosiques et leur méthode de préparation |
| WO1991002750A1 (fr) * | 1989-08-18 | 1991-03-07 | Biogen, Inc. | Nouveaux inhibiteurs de thrombine |
| US7371257B2 (en) | 1989-12-15 | 2008-05-13 | Boston Scientific Scimed, Inc. | Stent lining |
| US5135516A (en) * | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
| EP0442843A1 (fr) * | 1990-02-14 | 1991-08-21 | Pentapharm A.G. | Inhibiteur pour le prétraitement anticoagulant des échantillons sanguins |
| EP0551286A4 (en) * | 1990-10-04 | 1993-11-03 | New England Deaconess Hospital | Soluble hirudin conjugates |
| WO1992005749A1 (fr) * | 1990-10-04 | 1992-04-16 | New England Deaconess Hospital Corporation | Conjugues solubles d'un inhibiteur de la thrombogenese |
| WO1993010827A1 (fr) * | 1991-11-29 | 1993-06-10 | William Cook Europe A/S | Procede d'application d'un revetement hydrophile sur des surfaces en metal |
| CN112043877A (zh) * | 2020-08-06 | 2020-12-08 | 苏州大学 | 一种蚕丝抗凝血管支架覆膜及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK427079A (da) | 1979-10-10 |
| EP0015909A1 (fr) | 1980-10-01 |
| JPS55500091A (fr) | 1980-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4152075B2 (ja) | 表面改質物質を調整する新方法 | |
| CN109731137B (zh) | 具有生物抗污功能的白蛋白涂层的制备方法及具有生物抗污功能的材料 | |
| JP4489297B2 (ja) | ヘパリンを含む組成物の使用方法 | |
| CA2503490C (fr) | Revetement de surface pour dispositifs medicaux comprenant un compose bioactif | |
| CA1148468A (fr) | Articles empechant la formation de thrombus | |
| US4871357A (en) | Ionic heparin coating | |
| JPH05500314A (ja) | 改良されたイオン性ヘパリンコーティング | |
| EP0309473B1 (fr) | Produit adapte au contact du sang, procede pour sa preparation ainsi que ses applications | |
| WO1979000638A1 (fr) | Methode de production de surfaces permettant d'eviter la formation de thrombus | |
| AU6502590A (en) | Process for the preparation of surface modified solid substrates | |
| EP2968676A1 (fr) | Immobilisation de principe actif sur un substrat | |
| US8048437B2 (en) | Medical device with surface coating comprising bioactive compound | |
| EP2340057A2 (fr) | Entités biologiques immobilisées | |
| EP1021216A1 (fr) | Procede permettant de modifier des surfaces a l'aide d'un produit issu de la reaction d'un polymere insoluble dans l'eau et d'une imine polyalkylene | |
| EP0231573B1 (fr) | Revêtement ionique d'héparine | |
| CA1340800C (fr) | Articles comportant une surface hemocompatible, qu'un procede pour produire ce type d'articles | |
| JP4258703B2 (ja) | 血液適合性組成物およびそれをコートした医療用具 | |
| AU2317888A (en) | Articles exhibiting a blood-compatible surface layer and process for providing articles with such a surface layer | |
| JPH053916A (ja) | 血液中電解質センサ用被覆材料 | |
| JPH04146766A (ja) | 抗血栓性医用材料および医用器具 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Designated state(s): CH DE DK GB JP SE US |
|
| AL | Designated countries for regional patents |
Designated state(s): FR |